Drug Profile
PKI 179
Alternative Names: PKI-179Latest Information Update: 31 Dec 2009
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Antineoplastics; Morpholines; Organic chemicals
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Dec 2009 Discontinued - Phase-0 for Cancer in USA (PO)
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 13 Oct 2009 Phase-0 for Cancer in USA (PO)